Correlation between Blood UA，Smad1 Protein，Urine mALB Levels and the Therapeutic Effect of Dapagliflozin in Patients with Type 2 Diabetes Nephropathy

Mengxue LIU; Jia MIAO; Xuehe SHENG

doi:10.12259/j.issn.2095-610X.S20240425

Volume 45 Issue 4

Apr. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(4): 170-176

Mengxue LIU, Jia MIAO, Xuehe SHENG. Correlation between Blood UA，Smad1 Protein，Urine mALB Levels and the Therapeutic Effect of Dapagliflozin in Patients with Type 2 Diabetes Nephropathy[J]. Journal of Kunming Medical University, 2024, 45(4): 170-176. doi: 10.12259/j.issn.2095-610X.S20240425

Citation:

Mengxue LIU, Jia MIAO, Xuehe SHENG. Correlation between Blood UA，Smad1 Protein，Urine mALB Levels and the Therapeutic Effect of Dapagliflozin in Patients with Type 2 Diabetes Nephropathy[J]. Journal of Kunming Medical University, 2024, 45(4): 170-176. doi: 10.12259/j.issn.2095-610X.S20240425

Citation:

Mengxue LIU, Jia MIAO, Xuehe SHENG. Correlation between Blood UA，Smad1 Protein，Urine mALB Levels and the Therapeutic Effect of Dapagliflozin in Patients with Type 2 Diabetes Nephropathy[J]. Journal of Kunming Medical University, 2024, 45(4): 170-176. doi: 10.12259/j.issn.2095-610X.S20240425

PDF( 693 KB)

Correlation between Blood UA，Smad1 Protein，Urine mALB Levels and the Therapeutic Effect of Dapagliflozin in Patients with Type 2 Diabetes Nephropathy

doi: 10.12259/j.issn.2095-610X.S20240425

Dept. of Pharmacy，The 2nd Affiliated Hospital of Wannan Medical College，Wuhu Anhui 241000，China

Received Date: 2023-12-21
Available Online: 2024-04-06
Publish Date: 2024-04-29

Abstract

Abstract

Objective To observe the levels of uric acid, Smad1 protein, and urine microalbumin in patients with type 2 diabetic nephropathy, and to analyze the correlation between these three factors and the effectiveness of dapagliflozin in treating type 2 diabetic nephropathy. Methods From June 2021 to September 2022, 170 patients with type 2 diabetic nephropathy in our hospital were included in the diabetic nephropathy group. Another 120 patients with only type 2 diabetes during the same period were included in the simple diabetes group. All patients underwent blood UA, Smad1 protein, and urine mALB tests upon admission, and the levels of these three indicators were compared between the diabetic nephropathy group and the simple diabetes group. All type 2 diabetic nephropathy patients were treated with dapagliflozin and followed up for three months to observe the treatment effect. Based on the treatment effect, they were divided into the effective group （n = 142） and the ineffective group （n = 28）. The blood UA, Smad1 protein and urine mALB contents of the effective group and ineffective group were compared, and the correlation between the three indexes and the therapeutic effect of Dapagliflozin on type 2 diabetic nephropathy was analyzed. A receiver operating characteristic curve （ROC） was plotted to analyze the predictive value of the above three indicators for the effect of dapagliflozin treatment for type 2 diabetic nephropathy. Results Diabetic nephropathy group had higher levels of blood UA, Smad1 protein, and urine mALB compared to the simple diabetic group （t = 8.843, 12.097, 8.858, P < 0.05）. After 3 months of treatment, out of 170 type 2 diabetic nephropathy patients, 142 cases were effectively treated （83.53%）, while 28 cases were not （16.47%）. The ineffective group had higher levels of blood UA, Smad1 protein, and urine mALB compared to the effective group （t = 3.508, 4.622, 3.563, P < 0.05）. Correlation analysis showed that blood UA, Smad1 protein, and urine mALB levels were negatively correlated with the efficacy of Dapagliflozin treatment for type 2 diabetic nephropathy （r = -0.261, -0.336, -0.265, P < 0.05）. Logistic regression analysis indicated that elevated levels of blood UA （95%CI: 1.001～1.021）, Smad1 protein （95%CI: 1.167～1.610）, and urine mALB （95%CI: 1.011～1.048） were risk factors for the ineffectiveness of Dapagliflozin treatment for type 2 diabetic nephropathy （OR=1.011, 1.371, 1.029, P < 0.05）. The receiver operator characteristic curve （ROC） analysis showed that blood UA （95%CI: 0.622～0.793）, Smad1 protein （95%CI: 0.685～0.841）, and urine mALB （95%CI: 0.630～0.803） levels had some predictive value for the efficacy of Dapagliflozin treatment for type 2 diabetic nephropathy （AUC = 0.707, 0.763, 0.716）, with higher predictive value when combined （95%CI: 0.734～0.881, AUC = 0.808）. Conclusion The levels of serum UA, Smad1 protein and urine mALB are closely related to the therapeutic effect of Dapagliflozin on type 2 diabetic nephropathy, which can be used to predict its therapeutic effect.
- Type 2 diabetic nephropathy,
- Blood uric acid,
- Smad homologue 1 protein,
- Dapagliflozin

FullText(HTML)

References(22)

References

[1]	Crompton M,Ferguson J K,Ramnath R D,et al. PP18: Early mineralocorticoid receptor antagonism in diabetic nephropathy limits albuminuria by preserving the glomerular endothelial glycocalyx[J]. JCI Insight,2022,8(5):e154164.
[2]	Elkazzaz S K,Elkazzaz S K,El Fayoumi H M,et al. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats:Inflammation,angiogenesis and apoptosis[J]. Life Sci,2021,49(280):119018.
[3]	Sarafidis P,Ortiz A,Ferro C J,et al. Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: A new era has already begun[J]. J Hypertens,2021,39(6):1090-1097. doi: 10.1097/HJH.0000000000002776
[4]	Zhang D,Ye S,Pan T. The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes[J]. Peer J,2019,7(11):e7079.
[5]	Weisman A,Tomlinson G A,Lipscombe L L,et al. Allopurinol and renal outcomes in adults with and without type 2 diabetes: A retrospective,population-based cohort study and propensity score analysis[J]. Can J Diabetes,2021,45(7):641-649.e4. doi: 10.1016/j.jcjd.2021.01.005
[6]	Zou J,Zhou X,Ma Y,et al. Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad[J]. Biomed Pharmacother,2022,41(149):112931.
[7]	Tayel S I,Saleh A A,El-Hefnawy S M,et al. Simultaneous assessment of microRNA 126 and 192 in diabetic nephropathy patients and their relation with urinary albumin[J]. Curr Mol Med,2019,19(5):361-371.
[8]	中华医学会内分泌学分会. 中国成人糖尿病肾脏病临床诊断的专家共识[J]. 中华内分泌代谢杂志,2015,31(5):379-385. doi: 10.3760/cma.j.issn.1000-6699.2015.05.001
[9]	中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 2型糖尿病基层诊疗指南(实践版·2019)[J]. 中华全科医师杂志,2019,18(9):810-818. doi: 10.3760/cma.j.issn.1671-7368.2019.09.003
[10]	北京大学医学系糖尿病肾脏病专家共识协作组. 糖尿病肾脏病诊治专家共识[J]. 中华医学杂志,2020,100(4):247-260. doi: 10.3760/cma.j.issn.0376-2491.2020.04.003
[11]	Surendran S,Paul D,Pokharkar S,et al. A LC-MS/MS method for simultaneous estimation of a novel anti-diabetic combination of saxagliptin and dapagliflozin using a polarity switch approach: Application to in vivo rat pharmacokinetic study[J]. Anal Methods-UK,2019,11(2):219-226. doi: 10.1039/C8AY02087F
[12]	Kuzmin O B,Belyanin V V,Buchneva N V,et al. Sodium and glucose cotransporter type 2 inhibitors: A new class of drugs for the treatment of diabetic and non-diabetic nephropathy[J]. Nephrology,2021,25(4):33-41.
[13]	Su H,Liu T,Li Y,et al. Serum uric acid and its change with the risk of type 2 diabetes: A prospective study in China[J]. Prim Care Diabetes,2021,15(6):1002-1006. doi: 10.1016/j.pcd.2021.06.010
[14]	Dissanayake L V,Spires D R,Levchenko V,et al. The role of xanthine dehydrogenase (xdh) and uric acid in the kidney development and renal injury[J]. FASEB J,2020,34(1):1. doi: 10.1096/fj.201902914
[15]	Chen Y,Chen L,Yang T. Silymarin nanoliposomes attenuate renal injury on diabetic nephropathy rats via co-suppressing TGF-β/Smad and JAK2/STAT3/SOCS1 pathway[J]. Life Sci,2021,49(271):119197.
[16]	Chen X,Sun L,Li D,et al. Green tea peptides ameliorate diabetic nephropathy by inhibiting the TGF-β/Smad signaling pathway in mice[J]. Food Funct,2022,13(6):3258-3270. doi: 10.1039/D1FO03615G
[17]	Viazzi F,Russo G T,Ceriello A,et al. Natural history and risk factors for diabetic kidney disease in patients with T2D: Lessons from the AMD-annals[J]. Nephrol,2019,32(4):517-525. doi: 10.1007/s40620-018-00561-3
[18]	Palmer B F. Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes[J]. Diabetes Obes Metab,2023,25(6):1434-1443. doi: 10.1111/dom.15030
[19]	车艳苓,王海燕,李建格,等. 同型半胱氨酸与尿微量白蛋白联合检测在糖尿病肾病中的临床诊断价值[J]. 标记免疫分析与临床,2020,27(6):974-977.
[20]	吴小冬,尹宝枝. 2型糖尿病肾病患者尿液中MALB、红细胞及血液中铁蛋白水平与其病程的关系[J]. 国际泌尿系统杂志,2021,41(4):677-681. doi: 10.3760/cma.j.cn431460-20200803-00028
[21]	Zhang J,Zhang R,Wang Y,et al. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy[J]. J Diabetes Res,2019,7(9):1-9.
[22]	Cheeveewattanagul N,Cristian F,Guajardo yévenes,et al. Aptamer-functionalised magnetic particles for highly selective detection of urinary albumin in clinical samples of diabetic nephropathy and other kidney tract disease[J]. Anal Chim Acta,2021,75(1154):338302.

Relative Articles(20)

Relative Articles

[1]	Mengdan XU, Hong XIANG, Xiaolong GAO, Jin ZHANG, Haiyan WU, Lilin WANG. Effect of Dapagliflozin on Cardiac Structure and Function in Patients with Heart Failure Due to Mildly Reduced Ejection Fraction. Journal of Kunming Medical University, 2024, 45(11): 1-8.
[2]	Ling NIU, Boyi LI, Cuijuan MIAO, Cheng ZHANG, Yan TANG, Fang LIU, Rong MA. Relationship between Leptin，Uric Acid，and Obesity in Type 2 Diabetes Mellitus. Journal of Kunming Medical University, 2023, 44(11): 140-144. doi: 10.12259/j.issn.2095-610X.S20231121
[3]	Jianpei SU, Miyu HE, Yongli WANG, Qi WU, Weimeng TIAN, Jin LI, Bijuan LIANG. To Investigate the Application Effect of Dapagliflozin in Elderly Patients with HFpEF and Type 2 Diabetes Mellitus and Its Effect on Inflammatory Factors. Journal of Kunming Medical University, 2023, 44(4): 112-116. doi: 10.12259/j.issn.2095-610X.S20230405
[4]	Yuanqing CAO, Xiangyu ZI, Yankun ZHU, Baohong YUAN. Studies on the Correlation of Early Blood Uric Acid Fluctuation after Bariatric Surgery. Journal of Kunming Medical University, 2022, 43(9): 53-58. doi: 10.12259/j.issn.2095-610X.S20220924
[5]	Er-shu RUAN, Shuo WANG, Hui SU, Feng-qiong YIN, Zhong-yi QIAN, Jian-yu YANG. Effect of Ginsenoside Rg1 on Renal Protection in Type 2 Diabetic Rats. Journal of Kunming Medical University, 2021, 42(6): 50-55. doi: 10.12259/j.issn.2095-610X.S20210625
[6]	Qiong ZHOU, Bao-kun PENG, Xiao-chun WENG, Zhen JU, Nuo-pi-chu SUN, Zhe TANG. Clinical Characteristics of Newly Diagnosed Type 2 Diabetes Mellitus and Influencing Factors of Glycosylated Hemoglobin Among Tibetans in Deqin. Journal of Kunming Medical University, 2021, 42(8): 106-110. doi: 10.12259/j.issn.2095-610X.S20210819
[7]	Yi ZENG, Yun-juan LIAO, Ying LI, Zhen-kun HE. Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6. Journal of Kunming Medical University, 2021, 42(12): 41-46. doi: 10.12259/j.issn.2095-610X.S20211218
[8]	Zheng Lin Qiong , Lu Jing , Ye Ji Ming . . Journal of Kunming Medical University, 2019, 40(06): 90-92.
[9]	Zhang Wei Qiang , Li Ju Bao , Li Fan Bing . Effect of Taking-off Joint Gout Stone Operation on the Serum Uric Acid of Gout Patients. Journal of Kunming Medical University, 2017, 38(01): 61-64.
[10]	Wang Xiang Yun . . Journal of Kunming Medical University,
[11]	Lu Fang Li . . Journal of Kunming Medical University,
[12]	Wang Xing Ning . . Journal of Kunming Medical University,
[13]	Yang Bo . . Journal of Kunming Medical University,
[14]	Chen Xiao Hong . . Journal of Kunming Medical University,
[15]	Yang Jing . . Journal of Kunming Medical University,
[16]	Yang Jing . . Journal of Kunming Medical University,
[17]	Tang Li Li . . Journal of Kunming Medical University,
[18]	. Research of Platelet Membrane Glycoprotein PAC-1 and CD62P in Elderly Patients with Type 2 Diabetes,Impaired Glucose Tolerance and Impaired Fasting Glucose. Journal of Kunming Medical University,
[19]	Deng Zi Yu . . Journal of Kunming Medical University,
[20]	Li Mei Rui . . Journal of Kunming Medical University,